Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi comb...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Med Genomics
Autores principales: Omolo, Bernard, Yang, Mingli, Lo, Fang Yin, Schell, Michael J., Austin, Sharon, Howard, Kellie, Madan, Anup, Yeatman, Timothy J.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Technical Advance
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5069826/
https://ncbi.nlm.nih.gov/pubmed/27756306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-016-0225-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares